About TTP from Medical Journals

We are continuously adding new resource links to help ensure this page remains a hub of information to the TTP community. If you come across an informative source on the web, please let us know so that we can add it for others to easily find.

Articles are listed for your convenience. We do not endorse or recommend the contents.

Title  Description
ISTH Guidelines for the Diagnosis of TTP "The evidence-based guidelines of the ISTH are intended to support patients, clinicians, and other healthcare professionals in their decisions about the initial diagnosis and management of acute TTP."
Congentital TTP: toward a turning point. "The most important turning point for patients with congenital TTP may be in the near future. Documentation of silent organ injury together with the development of recombinant ADAMTS13 could provide the evidence and the method for lifetime ADAMTS13 replacement beginning at the time of diagnosis. VWF, von Willebrand factor."

COVID-19 and TTP: FAQs

The American Society of Hematology (ASH) has posted FAQs regarding new considerations for TTP treatment during the COVID -19 pandemic.
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. ...However, the very low incidence of TTP is an obstacle to the development of evidence-based clinical practice recommendations, and the very wide variability in survival rates across centers may be partly ascribable to diferences in management strategies due to insufcient guidance. We therefore developed an expert statement to provide trustworthy guidance about the management of critically ill patients with TTP. (November 2019)

A case for consideration by apheresis practitioners

This case report describes a patient with an aggressive course of TTP who subsequently developed metastatic melanoma while receiving prophylactic rituximab. (April 2019)
Primer:Thrombotic Thrombocytopenic Purpura Article serves as reference resource for experienced researchers and a useful broad introduction to the field for early career researchers and medical students. (April 2017). Author's research is funded by the Foundation.
Post-traumatic stress disorder and depression in survivors of TTP The study was conducted by a Clinical Fellow of Vanderbilt University Medical Center, Shruti Chaturvedi. Answering TTP Foundation spread the word about this very important research. There is more work to do. Register for the Answering TTP Community to receive invitations and updates like these. (January 2017)

Thrombotic Thrombocytopenic Pupura (TTP) Dinner Symposium Proceedings.

Answering TTP was established to engage the thrombotic thrombocytopenic purpura (TTP) community to further the common goals of patient support, education of patients and medical professionals, and the funding of research to improve the treatment and care of TTP patients. Answering TTP convened a dinner symposium on June 23, 2015 in Toronto, Canada during the International Society of Thrombosis and Haemostasis (ISTH) Congress to bring TTP clinicians and research together to highlight the key clinical and research questions in the field. These questions are increasingly important given the recent advances and novel therapies that have or will soon enter clinical study for patients with TTP. (June 2016)

A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.

The primary objective of this phase II study was to evaluate the efficacy of rituximab in the management of adult patients with physician-diagnosed presumed thrombotic thrombocytopenic purpura (TTP); relapsed or refractory.  (April 2015)

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

Results of phase 2 controlled study to investigate a new drug's ability to reduce treatment time, when administered in addition to the standard-of-care. (February 2016)
Advances in Understanding and Treatment of TTP MD Conference Express. Pages 11 - 13. (August 2015)
Provides an overview of the TTP therapeutic pipeline. (March 2015)
ADAMTS13 and Pregnancy Relapse ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. (Jan 2011)
ADAMTS13 testing: why bother? In this issue of Blood, Kremer Hovinga and colleagues demonstrate that a lower level of initial plasma ADAMTS13 activity (< 10%) is associated with higher risk of relapse in patients with TTP.
Adjunctive treatments Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. (Jan 2012)
Epidemiology Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes.(Nov 2010)
How I treat patients with thrombotic thrombocytopenic purpura: 2010 How I treat patients with thrombotic thrombocytopenic purpura: 2010 James N. George (August 2010)
Korean TTP registry Experience Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. (Feb 2011)
Long-term Long-term deficits in health-related quality of life after recovery from TTP (Jan 2009)
Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura. (July 2011)
Neurologic Injury Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.(Jan 2011)
Pathogenesis and Treatment Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura (Sept 2010)
Pathophysiology of thrombotic thrombocytopenic purpura Pathophysiology of thrombotic thrombocytopenic purpura (Jan 2010)
Prophylactic Cyclosporine Therapy Effect of Prophylactic Cyclosporine Therapy on ADAMTS13 Biomarkers in Patients with Idiopathic Thrombotic Thrombocytopenic Purpura (Feb 2010)
Rituximab as pre-emptive treatment Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. (Feb 2009)
Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. (December 2010)
Severity of Relapse Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. (December 2010)
Survival and relapse Survival and relapse in patients with thrombotic thrombocytopenic purpura. (Feb 2010)
TTP and ADAMTS13 TTP --- the role of ADAMTS13 assay in clinical practice. (Sept. 2010)
TTP and ADAMTS13 When is Testing Appropriate (2007)
TTP Complications during Pregnancy Clinical study on five cases of thrombotic thrombocytopenic purpura complicating pregnancy. (Dec 2010)
TTP & UTI Thrombotic thrombocytopenic purpura and urinary tract infections: is there a connection? (Jan 2011)
Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination Case study(Sept 2010)
Laparoscopic splenectomy for the treatment of refractory thrombotic thrombocytopenic purpura Report on the surgical and homological outcomes of laparoscopic splenectomy (LS) in a patient with refrectory TTP.
Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes A report on 103 acute clinical episodes of 21 patients during a time period of 30 years. (May 2013)
Management and outcomes for patients with TTP: analysis of 100 cases at a single institution A Study done at the Cleveland Clinic between 2000-2012 to identify factors predictive of poor outcomes. (April 2013)
Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura The use of in silico tools that examine multiple mutation characteristics may better predict phenotype. (March 2013)
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura In this issue of Blood, Miguel Hie and colleagues demonstrate that preemptive infusions of rituximab in remission significantly decrease TTP relapse rate. (July 2014)
Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab Study to determine if patients with TTP treated with Plasma Exchange and Rituximab experienced relapses. (July 2013)
Thrombotic Microangiopathies A paper about TMAs.
Thrombotic Microangiopathy Thrombotic Microangiopathy history and individual overviews.
Thrombotic Microangiopathy and Associated Renal Disorders This review addresses the current understanding of molecular mechanisms underlying TMA.
Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, and Thrombotic Thrombocytopenic Purpura A paper on TMAs
Thrombotic thrombocytopenia purpura survivors may be at risk for poor health Review of study results. (Sept. 2013)